Navigation Links
Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
Date:11/5/2007

TSX Exchange Symbol: RVX

ORLANDO, FL, Nov. 5 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208, at the American Heart Association Scientific Meetings. The presentation titled "Oral Administration of Compound RVX-208 Increases Serum Levels of ApoA-I and Improves High-Density Lipoprotein-Mediated Cholesterol Efflux in African Green Monkeys" was presented by Dr. Jacques Genest.

Dr. Jacques Genest, MD, Director of the Division of Cardiology at McGill University Health Centre/Royal Victoria Hospital said, "We were excited about this data and felt that it should be presented at this prestigious conference. Resverlogix's novel drug demonstrated the ability to increase the production of ApoA-I and functional HDL. Notably we saw increases in pre beta HDL sub particles, which improve HDL's ability to mediate cholesterol efflux."

"We are very pleased to have our data presented at one of the most prestigious conferences for cardiovascular disease," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Clinical Affairs of Resverlogix. "Our small molecule, RVX-208, by virtue of increasing endogenous production of ApoA-I and functional HDL has huge potential to address the unmet medical need of cardiovascular disease," added Dr Johansson.

Apolipoprotein A-I (ApoA-I), the main component of high-density lipoprotein (HDL) represent the bodies natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that of the vessel wall to the liver for processing. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in animals and humans. In his presentation Dr. Genest discussed the effects of oral administration of RV
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. Viragen International to Reverse Split Its Common Stock
3. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
4. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
5. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
6. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
7. Mechanism for the in-vivo transport of siRNA
8. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Research and Markets ( ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing ... - Global Version" report to their offering. ... area of molecular diagnostics and pharmacogenics hold the ... market that is moving out of the national ...
(Date:5/5/2015)... , May 5, 2015   Tocagen Inc. ... David R. Parkinson , M.D., a venture ... appointed to the board of directors of Tocagen. ... experience in oncology clinical development, including leading clinical ... global approvals of the cancer therapeutics Gleevec®, Femara®, ...
(Date:5/5/2015)... May 05, 2015 Synedgen Inc. is ... as Regulatory Affairs Manager. , Dr. Nguyen brings to ... juncture for the company as it moves forward in ... over the next two years. Dr. Nguyen will lead ... the regulatory key documents that must be completed in ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - JSS Medical Research Inc., a ... that it concluded the acquisition of Max Neeman International (MNI), with ... regional offices are located in Ahmedabad, Bangalore , ... Through a US subsidiary, a regional office is located ... is supported by the recent equity investment transaction into JSS with ...
Breaking Biology Technology:Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4Synedgen Announces the Appointment of Regulatory Affairs Manager 2JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4
... Kendle (Nasdaq: KNDL ), a,leading, global ... Executive Officer Candace Kendle, PharmD, will,participate in the ... be held at the Grand Hyatt New York, ... 22-25, 2008. Kendle,s presentation is,scheduled for Wednesday, September ...
... Del., Sept. 22 For,his lifetime commitment in the ... other environmental exposures on the developing fetus and for,his ... Brent, MD, PhD, will be honored as the recipient ... in Children,s Health Care by Nemours,one of the nation,s ...
... US Medtech Report, WASHINGTON, Sept. 22 ... remained strong over the past 18 months,despite a ... due to the,global credit crunch. At the same ... produced solid growth in revenues and,earnings, driven by ...
Cached Biology Technology:Robert L. Brent, MD, PhD, Honored with 2008 Alfred I. duPont Award for Excellence in Children's Health Care 2Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets 2Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets 3Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets 4
(Date:4/6/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM FOR ... introduces a new revolutionary method and system to ... of miniature antenna modules for multiple purposes including ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... 2013 - Ontario Genomics Institute (OGI) congratulates Cytognomix ... Pipeline, which was recently purchased by the National ... OGI invested in Cytognomix through its Pre-commercialization Business ... data generated by next-generation sequencing is essential to ...
... MASON, Ohio , April 26, 2013 /PRNewswire-iReach/ -- ... joined forces to bundle Haag-Streit,s Octopus perimeter with Optovue,s ... will be distributed by Optovue in the ... to partner with Optovue for its leadership in OCT ...
... Onieva, has undertaken research for her PhD thesis on ... sheep and goats. In concrete, she investigated if these ... they could be used in preventing certain diseases of ... The thesis is titled Inmunidad innata frente a ...
Cached Biology News:OGI's investment in cytognomix contributes to the Shannon Human Splicing Pipeline's success 2Haag-Streit USA and Optovue Team Up to Introduce Octopus/Optovue Bundle 2Haag-Streit USA and Optovue Team Up to Introduce Octopus/Optovue Bundle 3Innate immunity system of sheep and goat herds against viral infections clarified 2
... 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... to 1 mg/ml,(0.26 M to 2.6 mM) Sensitivity: around 0.2 ug/ml ...
... Panomer 9 oligodeoxynucleotides are ... labeled at the 5' ... Alexa Fluor dyes and ... assessing microarray spot morphology, ...
... l-[U-14C]methionine, 1.85 MBq, 50 uCi. Aqueous ... > 1.85 GBq/mg atom carbon, > ... of Ala, Arg, Asp, Glu, Gly, ... Ser, Thr, Tyr and Val.1.85 MBq/ml, ...
Alkaline Phosphatase Stabilizer Solution, 1 L...
Biology Products: